6003 The correlation between Topoisomerase-I (Topo1) expression and outcome of treatment with capecitabine and irinotecan in advanced colorectal cancer (ACC) patients (pts) treated in the CAIRO study of the Dutch Colorectal Cancer Group (DCCG)

M.Koopman; N.Knijn; S.Richman; M.Seymour; P.Quirke; H.van Tinteren; J.H.J.M.van Krieken; C.J.A.Punt; I.D.Nagtegaal

首页> 外文期刊>European Journal of Cancer Supplements >6003 The correlation between Topoisomerase-I (Topo1) expression and outcome of treatment with capecitabine and irinotecan in advanced colorectal cancer (ACC) patients (pts) treated in the CAIRO study of the Dutch Colorectal Cancer Group (DCCG)

【24h】

6003 The correlation between Topoisomerase-I (Topo1) expression and outcome of treatment with capecitabine and irinotecan in advanced colorectal cancer (ACC) patients (pts) treated in the CAIRO study of the Dutch Colorectal Cancer Group (DCCG)

机译：6003在荷兰大肠癌组（DCCG）的CAIRO研究中治疗的晚期大肠癌（ACC）患者（pts）中拓扑异构酶I（Topo1）表达与卡培他滨和伊立替康治疗结果之间的相关性

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2009年第2期|共2页
作者
M.Koopman; N.Knijn; S.Richman; M.Seymour; P.Quirke; H.van Tinteren; J.H.J.M.van Krieken; C.J.A.Punt; I.D.Nagtegaal;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 3000 ORAL Randomised phase III study of capecitabine, oxaliplatin and bevacizumab (CAPOX-B) with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim safety analysis [J] . J.Tol, M.Koopman, C.J.Rodenburg, European Journal of Cancer Supplements . 2007,第4期

机译：3000口服卡培他滨，奥沙利铂和贝伐单抗（CAPOX-B）联合或不联合西妥昔单抗治疗晚期大肠癌（ACC）的III期随机研究，荷兰大肠癌组（DCCG）的CAIRO2研究。临时安全分析
2. 600 ORAL Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (ACC), an interim safety analysis. a Dutch Colorectal Cancer Group (DCCG) phase III study [J] . European Journal of Cancer Supplements . 2005,第2期

机译：600口服凯培他滨，伊立替康和奥沙利铂序贯化疗与联合化疗在晚期大肠癌（ACC）中的随机研究，一项临时安全性分析。荷兰结肠直肠癌小组（DCCG）的III期研究
3. 3015 ORAL Sequential vs. combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (ACC). A Dutch Colorectal Cancer Group (DCCG) phase III study [J] . M.Koopman, N.F.Antonini, J.Douma, European Journal of Cancer Supplements . 2007,第4期

机译：3015口服卡培他滨，伊立替康和奥沙利铂序贯联合化疗联合治疗晚期大肠癌（ACC）。荷兰结肠直肠癌小组（DCCG）的III期研究
4. Availability and Usability of the Hospital-based Cancer Registry Data for Measuring the Quality Outcome Indicators of Healthcare Provided to Breast and Colorectal Cancer Patients at King Hussein Cancer Center [C] . Amid Abu Hmaidan, Elsie Boutou, Khaled Jamal, International Conference on Cancer Care Informatics . 2018

机译：基于医院的癌症登记系统数据的可用性和可用性，用于测量侯赛因国王癌症中心提供给乳腺癌和结直肠癌患者的医疗保健质量结果指标
5. Use and outcomes of newer chemotherapeutic agents in colorectal cancer patients using Irinotecan as a case study. [D] . Obeidat, Nour A. 2008

机译：以伊立替康为例的结直肠癌患者中新型化疗药物的使用和结果。
6. Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG) [O] . Joost Huiskens, Thomas M van Gulik, Krijn P van Lienden, 2015

机译：最初无法切除的仅肝转移的大肠癌患者的治疗策略荷兰大肠癌组（DCCG）的随机3期CAIRO5研究的研究方案
7. Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG) [O] . 2015

机译：最初无法切除的仅肝转移的大肠癌患者的治疗策略，荷兰大肠癌组（DCCG）的随机3期CAIRO5研究的研究方案

6003 The correlation between Topoisomerase-I (Topo1) expression and outcome of treatment with capecitabine and irinotecan in advanced colorectal cancer (ACC) patients (pts) treated in the CAIRO study of the Dutch Colorectal Cancer Group (DCCG)

著录项

相似文献

相关主题

期刊订阅